Study wrapper · #928
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
Pearson MJ, Willency JA, Lin Y, et al. The Journal of clinical endocrinology and metabolism. 2026.
DOI: 10.1210/clinem/dgag201PubMed: 42135195
Editor's note
This is a pre-specified post-hoc metabolomic and lipidomic analysis drawn from two randomized, placebo-controlled phase 2 trials, so the underlying design is strong though the analysis is exploratory. Higher retatrutide doses were associated with biomarker shifts linked to fatty acid oxidation and lower insulin resistance. Findings are mechanistic and hypothesis-supporting rather than clinical endpoints.
Plain-language abstract
A post-hoc analysis of two randomized phase 2 trials found retatrutide was associated with changes in fat-metabolism and insulin-resistance-related biomarkers consistent with improved metabolic health.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026